Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > Chilled cheese
View:
Post by donkeyfeathers on May 10, 2021 10:24am

Chilled cheese

To further my point, big pharma is just like all of us investors, except they have way more to gain.

 

If we are saying that Big Pharma invests in this like retail investors, then the part about them still not investing in this like we already have, is baffling.  I suggest that big Pharma was interested in retail investors taking on all of the risk exposure up until January 2021, and even now the claim that big Pharma has “way more to gain” only happens if they see themselves being able to get this platform to a place of commercialization before patents run out.  In addition, they would much rather be dealing with an entity that is closely held rather than publicly traded, because they too now deal with intermediaries (L/J + Cncd) that don’t always smooth new partnerships.

 

If you think immune protection technology is so important, then why did you buy into the company before it was ready? Why can't big pharma get involved for that exact same reason?

 

I’ll start with answering the second question first.  I have stated on this forum that should we get to a place where immune protection is shown to be viable in conjunction with the platform, the market will respond with valuations at multiples higher than we are at today.  But again, that risk and exposure to exactly when viability is achieved - no harmful immune-suppressants required -  may mean we are holders of a great platform that doesn’t actually capture the diabetes market because we are too late to market (hemo and thyroid then become our real hope).  This company went out and got islets through UHN and conformal coatings, but where is the cash needed to put this all together?  Is $30 mil enough? Nuh-uh.

I bought in because I knew a platform that kept cells alive was just as important as coatings around cells or an ample supply of cells.  I’m not sure what will cause big Pharma to get involved, but my guess is those that make those decisions see way more potential potholes than what I saw, meaning they’d NEVER get in for the same reason I have.  And some now on our BOD may be the ones telling Pharma to hold their $$$ as leverage, for the big bill of confirming the efficacy prior to transplanting everyone without the need for drugs.  The idea that we (now) have people who “know each other from other lives” cuts both ways (I’m afraid in a selfie kind of way).

 

You can't respond because everything you say I easily poke holes through like swiss cheese.

 

I happen to be a big fan of Swiss cheese except for when someone uses it first as their love toy.  You know what they say…the hole size tells us a lot about the calibre of the probe…

This comment sounded like someone who started out trying to show up inconsistencies in logic (fine) and then part way through, began to sense a threat that others on here who have some serious reservations about what happens in the next 3 months (we’re way past waiting another 1-2 years) might just be right about not blindly accepting the CEO/BOD direction taken since this year began.  I’d suggest that if you want to be taken seriously that you keep your “Poker” comments closely held.

 

Just delete your account bud, you bring no value to the conversation 

 

I’ve heard conversational value can be measured by ones ability to see two sides of a problem at the same time - before they speak.  Praise where due, criticism where appropriate.  Then there’s the “ignore” function.  Oddly enough, even those who I strongly disagree with on here, I still read what they have to say because just about everything from conspiracy theories to naivet still holds a bit of truth.  Your back of the napkin assumptions were fine (if a little crude/light).  You have your valuations.  Big Pharma once again uses models of a much greater sophistication.  Let’s hope that the horses we bet on are more sophisticated than the folks who might want to take us out.  Otherwise yours, mine and many other’s recent gains will be deleted in short order.

DF

Comment by MoneyMouth on May 10, 2021 12:13pm
 the claim that big Pharma has “way more to gain” only happens if they see themselves being able to get this platform to a place of commercialization before patents run out. Sernova's patent's are good through 2030. That gives us 9 years, maybe less until we have to actually cough up the cash to refile, but nonetheless, that gives quite a lot of time for trials and other developments ...more  
Comment by donkeyfeathers on May 10, 2021 12:52pm
Intermediaries like LJ+Cncd may not have aligned (timelines, targets etc.) objectives with the science.  Assuming they do - like that of assuming an angel investor is thinking the same as the inventor - is a rather large leap of faith.   The $4.5 mil is what they have committed to conformal coating with no guarantees that that will be enough.  We’ll see I guess.  In the ...more  
Comment by MoneyMouth on May 10, 2021 1:39pm
Maybe they are not aligned, but would they really have the pull to influence business decisions? They invested money, but I don't believe they were also given a seat at the table to tell Sernova what to do. Perhaps, Sernova can ask for their advice, but I don't think they can outright sway decisions.  Even if $4.5 mil is not enough, we still have extra cash to inject into the project ...more  
Comment by MustangSalley on May 10, 2021 9:24pm
  Cc/LJ basically covered most of the their shorts by taking the price down from $2.80 to $1.20 from the free trading paper they got from awful bought deal Tolekis gave away . There is no anslyst report or insitutional investors from Canacorrd and LJ.  They have 20 million shares or warrants at $1.70 that will be force converted at $3.05 .  Every time Toleikis calls them , they ...more  
Comment by cowjazz on May 11, 2021 1:19pm
This post has been removed in accordance with Community Policy
Comment by Metalsguy1 on May 11, 2021 1:36pm
I completely disagree. If we replaced the dead weight on the board and got a well known powerhouse to drive the company, our shares would be anything but wallpaper.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities